Who Benefits the Most From Adjuvant Durvalumab After Chemoradiotherapy for Non-small Cell Lung Cancer? An Exploratory Analysis

Practical Radiation Oncology - Tập 11 - Trang e172-e179 - 2021
Nitin Ohri1, Balazs Halmos2, William R. Bodner1, Haiying Cheng2, Madhur K. Garg1, Rasim Gucalp2, Chandan Guha1
1Department of Radiation Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, The Bronx, New York
2Department of Hematology/Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, The Bronx, New York

Tài liệu tham khảo

Ettinger, 2018, NCCN guidelines insights: Non-small cell lung cancer, version 5.2018, J Natl Compr Canc Netw, 16, 807, 10.6004/jnccn.2018.0062

Antonia, 2017, Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer, N Engl J Med, 377, 1919, 10.1056/NEJMoa1709937

Antonia, 2018, Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC, N Engl J Med, 379, 2342, 10.1056/NEJMoa1809697

Bhat, 2013, Neutrophil to lymphocyte ratio and cardiovascular diseases: A review, Expert Rev Cardiovasc Ther, 11, 55, 10.1586/erc.12.159

Azab, 2011, Neutrophil-lymphocyte ratio as a predictor of adverse outcomes of acute pancreatitis, Pancreatology, 11, 445, 10.1159/000331494

Templeton, 2014, Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis, J Natl Cancer Inst, 106, 10.1093/jnci/dju124

Hanahan, 2011, Hallmarks of cancer: The next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013

Tavakkoli, 2019, A novel paradigm between leukocytosis, G-CSF secretion, neutrophil-to-lymphocyte ratio, myeloid-derived suppressor cells, and prognosis in non-small cell lung cancer, Front Oncol, 9, 295, 10.3389/fonc.2019.00295

Diem, 2017, Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab, Lung Cancer, 111, 176, 10.1016/j.lungcan.2017.07.024

Bagley, 2017, Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer, Lung Cancer, 106, 1, 10.1016/j.lungcan.2017.01.013

Sacdalan, 2018, Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: A review and meta-analysis, Onco Targets Ther, 11, 955, 10.2147/OTT.S153290

Tang, 2014, Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes, Int J Radiat Oncol Biol Phys, 89, 1084, 10.1016/j.ijrobp.2014.04.025

Contreras, 2018, Cardiac dose is associated with immunosuppression and poor survival in locally advanced non-small cell lung cancer, Radiother Oncol, 128, 498, 10.1016/j.radonc.2018.05.017

Ladbury, 2019, Impact of radiation dose to the host immune system on tumor control and survival for stage III non-small cell lung cancer treated with definitive radiotherapy, Int J Radiat Oncol Biol Phys, 105, 346, 10.1016/j.ijrobp.2019.05.064

Ohri, 2018, Positron emission tomography—adjusted intensity modulated radiation therapy for locally advanced non-small cell lung cancer, Int J Radiat Oncol Biol Phys., 102, 709, 10.1016/j.ijrobp.2017.10.032

Mauguen, 2013, Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: A re-analysis of meta-analyses of individual patients' data, Lancet Oncol, 14, 619, 10.1016/S1470-2045(13)70158-X

Albain, 2009, Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: A phase III randomised controlled trial, Lancet, 374, 379, 10.1016/S0140-6736(09)60737-6

Van Meerbeeck, 2007, Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIa-n2 non-small-cell lung cancer, J Natl Cancer Inst, 99, 442, 10.1093/jnci/djk093

Thông tin
Thông tin xuất bản

Practical Radiation Oncology

Tập 11

e172-e179

Thông tin tác giả